SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes
EQS Group
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Preliminary Results
SCHOTT Pharma confirms outlook for FY 24..